Newsroom

LONDON--(BUSINESS WIRE)--AM Best has affirmed the Financial Strength Rating of B (Fair) and the Long-Term Issuer Credit Rating of “bb” (Fair) of Adamjee Insurance Company Limited (Adamjee) (Pakistan). The outlook of these Credit Ratings (ratings) is negative.The ratings reflect Adamjee’s balance sheet strength, which AM Best assesses as adequate, as well as its strong operating performance, neutral business profile and marginal enterprise risk management (ERM).The negative outlooks reflect press...

DALLAS--(BUSINESS WIRE)--Generational Capital Markets announces the sale of a structural steel fabricator and a steel erection company, to Crosstown Capital Partners....

LONDON--(BUSINESS WIRE)--  Re: International Finance Corporation   AZN 10,000,000.00   MATURING: 08-Sep-2027   ISIN: XS3176095076     PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 08-Sep-2025 TO 08-Sep-2026 HAS BEEN FIXED AT 7.80 PCT   DAY BASIS: ACTUAL/365(FIX)   INTEREST PAYABLE VALUE 08-Sep-2026 WILL AMOUNT TO: AZN 4,588.24 PER AZN 100,000.00 DENOMINATION  ...

LOS ANGELES--(BUSINESS WIRE)--Met het wereldwijd stijgende aantal seksueel overdraagbare aandoeningen (SOA's), vraagt de AIDS Healthcare Foundation (AHF) ter gelegenheid van de Internationale Dag van de Seksuele Gezondheid aan overheden en gezondheidszorgstelsels om een bredere toegang te bieden tot preventie-, test- en behandelingsdiensten voor hiv en andere SOA’s. Ondanks bewezen middelen om hiv en andere SOA’s te voorkomen, te diagnosticeren en te behandelen, blijven tekortkomingen in de toe...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) common stock between December 29, 2025 and June 29, 2026, inclusive (the “Class Period”). Unicycive Therapeutics, Inc. investors have until November 2, 2026 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN UNICYCIVE THERAPEUTICS, INC. (UNCY)...

LONDON--(BUSINESS WIRE)--  Re: TSB BANK plc.   GBP 500,000,000.00   MATURING: 11-Sep-2029   ISIN: XS2898163568     PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 11-Jun-2026 TO 11-Sep-2026 HAS BEEN FIXED AT 4.28 PCT   DAY BASIS: ACTUAL/365(FIX)   INTEREST PAYABLE VALUE 11-Sep-2026 WILL AMOUNT TO: GBP 5,391,225.21 PER GBP 500,000,000.00 DENOMINATION  ...

LONDON--(BUSINESS WIRE)--  Re: The Toronto-Dominion Bank (Covered Bonds)   GBP 800,000,000.00   MATURING: 11-Jun-2029   ISIN: XS2838372113     PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 11-Jun-2026 TO 11-Sep-2026 HAS BEEN FIXED AT 4.35 PCT   DAY BASIS: ACTUAL/365(FIX)   INTEREST PAYABLE VALUE 11-Sep-2026 WILL AMOUNT TO: GBP 8,767,111.01 PER GBP 800,000,000.00 DENOMINATION  ...

LOS ÁNGELES--(BUSINESS WIRE)--Mientras las infecciones de transmisión sexual siguen aumentando en todo el mundo, AIDS Healthcare Foundation ( AHF ) celebra el Día Mundial de la Salud Sexual haciendo un llamado a los gobiernos y a los sistemas de salud para que amplíen el acceso a los servicios de prevención, pruebas y tratamiento del VIH y otras ITS. A pesar de que existen herramientas probadas para prevenir, diagnosticar y tratar el VIH y otras ITS, las brechas en el acceso siguen poniendo en...

SÃO PAULO--(BUSINESS WIRE)--Ant International, the leading global digital payment, digitisation, and FinAI solutions provider, today announced that it has received a Payment Institution (PI) licence from the Central Bank of Brazil. “With the Central Bank's invaluable support, we are ready to step up more reliable and comprehensive global payment and account services to enterprises, platforms and SMEs in the country's dynamic digital economy, in ever deeper collaboration with its highly develope...

DUBLIN--(BUSINESS WIRE)--Mainstay Medical Holdings plc a annoncé aujourd’hui la publication des résultats de l’évaluation à deux ans de l’essai clinique randomisé RESTORE portant sur le ReActiv8, destiné au traitement des lombalgies chroniques réfractaires. Les données montrent une amélioration continue de l'invalidité liée aux douleurs dorsales, de la douleur et de la qualité de vie dans le groupe traité par ReActiv8, ainsi que des améliorations après un an de traitement par ReActiv8 dans le g...